Stockscreener 앱 받기
37.32
2.79%
-1.07
시장 영업 전:
37.75
0.43
+1.15%
전일 마감가:
$38.39
열려 있는:
$38.59
하루 거래량:
236.50K
Relative Volume:
1.18
시가총액:
$618.31M
수익:
$102.48M
순이익/손실:
$-191.09M
주가수익비율:
-2.588
EPS:
-14.4203
순현금흐름:
$-178.93M
1주 성능:
+7.58%
1개월 성능:
+56.94%
6개월 성능:
+279.23%
1년 성능:
+255.43%
1일 변동 폭
$36.31
$39.74
1주일 범위
$31.76
$39.74
52주 변동 폭
$6.736
$39.74
Sutro Biopharma Inc Stock (STRO) Company Profile
명칭
Sutro Biopharma Inc
전화
650-392-8412
주소
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare STRO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
STRO
Sutro Biopharma Inc
|
37.32 | 618.31M | 102.48M | -191.09M | -178.93M | -14.42 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-07 | 개시 | Leerink Partners | Outperform |
| 2026-03-24 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2026-03-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2026-01-20 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-06-16 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-03-17 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-03-14 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2025-03-14 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2024-05-08 | 개시 | BofA Securities | Buy |
| 2023-11-09 | 개시 | Deutsche Bank | Buy |
| 2023-10-06 | 개시 | Oppenheimer | Outperform |
| 2023-03-21 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-08-18 | 재개 | Wells Fargo | Overweight |
| 2021-06-18 | 개시 | H.C. Wainwright | Buy |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-09-02 | 개시 | Jefferies | Buy |
| 2020-07-16 | 개시 | Wells Fargo | Overweight |
| 2020-01-13 | 개시 | SunTrust | Buy |
| 2019-10-07 | 개시 | BTIG Research | Buy |
| 2019-07-18 | 개시 | Deutsche Bank | Buy |
| 2019-04-29 | 개시 | H.C. Wainwright | Buy |
| 2018-10-22 | 개시 | JMP Securities | Mkt Outperform |
| 2018-10-22 | 개시 | Piper Jaffray | Overweight |
| 2018-10-22 | 개시 | Wedbush | Outperform |
모두보기
Sutro Biopharma Inc 주식(STRO)의 최신 뉴스
Sutro Biopharma (NASDAQ:STRO) Upgraded at Lifesci Capital - MarketBeat
Citizens Raises Sutro Biopharma Price Target to 41 Dollars - HarianBasis.co
Point72 group (NASDAQ: STRO) reports 5.7% stake — 946,829 shares - Stock Titan
Sutro Biopharma (NASDAQ:STRO) Upgraded by Mizuho to "Strong-Buy" Rating - MarketBeat
Citizens Lifts PT on Sutro Biopharma (STRO) on Its Pipeline and Lead Program - Insider Monkey
Mizuho initiates coverage of Sutro Biopharma (STRO) with outperform recommendation - MSN
Sutro Biopharma: Recycling Past Data Ahead Of The Readout, Sell - Seeking Alpha
MSN Money - MSN
This Palantir Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday - Benzinga
Mizuho Securities Initiates Sutro Biopharma(STRO.US) With Buy Rating, Announces Target Price $50 - Moomoo
Short Interest in Sutro Biopharma, Inc. (NASDAQ:STRO) Grows By 17.0% - MarketBeat
Mizuho Initiates Sutro Biopharma at Outperform With $50 Price Target - marketscreener.com
STRO Initiated Coverage by Mizuho -- Rating Set at Outperform - GuruFocus
Mizuho initiates Sutro Biopharma stock coverage with outperform rating By Investing.com - Investing.com India
Mizuho initiates Sutro Biopharma stock coverage with outperform rating - Investing.com
Sutro Biopharma (NASDAQ:STRO) Hits New 1-Year HighWhat's Next? - MarketBeat
Sutro Biopharma Strengthens Financial Position and Advances ADC Pipeline - HarianBasis.co
Here is Why Sutro Biopharma (STRO) is One of the Tiny Stocks That Are On Fire Right Now - Insider Monkey
5 Tiny Stocks That Are On Fire Right Now - Insider Monkey
Sutro Biopharma (NASDAQ:STRO) Shares Up 5.6%What's Next? - MarketBeat
Sutro Biopharma (STRO) price target decreased by 21.62% to 29.58 - MSN
Sutro Biopharma prices $110M common stock offering - MSN
Sutro Biopharma, Inc. (STRO) Presents at AACR Annual Meeting 2026Slideshow (NASDAQ:STRO) 2026-04-24 - Seeking Alpha
Sutro Biopharma (NASDAQ:STRO) Shares Down 6.1%Time to Sell? - MarketBeat
STRO Maintains by Citizens -- Price Target Raised to $41.00 - GuruFocus
Citizens Jmp Boosts Sutro Biopharma (NASDAQ:STRO) Price Target to $41.00 - MarketBeat
Citizens raises Sutro Biopharma stock price target on platform value By Investing.com - Investing.com Canada
Citizens JMP Maintains Sutro Biopharma(STRO.US) With Buy Rating, Raises Target Price to $41 - Moomoo
STRO (Sutro Biopharma Inc.) posts 65.2 percent year over year revenue growth but misses EPS estimates, sending shares slightly lower.Restructuring - Cổng thông tin điện tử tỉnh Lào Cai
STRO Sutro Biopharma Q4 2025 EPS misses estimates, shares rise 3.01 percent on strong 65.2 percent revenue growth.High Interest Stocks - Xã Thanh Hà
Sutro Biopharma (NASDAQ: STRO) outlines 2026 vote on board, pay and auditor - Stock Titan
STRO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Millennium entities report 210,378 shares in Sutro Biopharma (STRO) — joint filing - Stock Titan
Perceptive Advisors, Joseph Edelman report 5.4% stake in Sutro Biopharma (NASDAQ: STRO) - Stock Titan
Sutro Biopharma (NASDAQ:STRO) Reaches New 1-Year HighStill a Buy? - MarketBeat
Sutro Biopharma, Inc. $STRO Shares Sold by JPMorgan Chase & Co. - MarketBeat
Sutro Biopharma presents promising preclinical data on ADC pipeline at AACR Annual Meeting - Traders Union
Sutro Biopharma (STRO) Reveals Strong Preclinical Results for Ne - GuruFocus
Sutro Biopharma Presents Promising Preclinical Data For Pipeline ADC Programs At AACR 2026 - RTTNews
Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026 - The Manila Times
Sutro Biopharma Reports Promising Preclinical Data for Next-Generation ADCs STRO-004, STRO-006, and STRO-227 at AACR Annual Meeting 2026 - Quiver Quantitative
Sutro's cancer drug candidate outperformed benchmark ADCs in lab models - Stock Titan
Sutro Biopharma, Inc. (NASDAQ:STRO) Short Interest Up 20.1% in March - MarketBeat
Sutro Biopharma (NASDAQ:STRO) Trading Up 10.4% After Analyst Upgrade - MarketBeat
STRO Maintained by Citizens -- Price Target Raised to $35.00 - GuruFocus
Sutro Biopharma (NASDAQ:STRO) Stock Price Expected to Rise, Citizens Jmp Analyst Says - MarketBeat
Citizens raises Sutro Biopharma stock price target on pipeline value By Investing.com - Investing.com Canada
Citizens JMP Maintains Sutro Biopharma(STRO.US) With Buy Rating, Raises Target Price to $35 - Moomoo
Sutro Biopharma Hits New 52-Week High - National Today
Sutro Biopharma (NASDAQ:STRO) Reaches New 52-Week HighHere's What Happened - MarketBeat
Sutro Biopharma Inc (STRO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Sutro Biopharma Inc 주식 (STRO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Chung Jane | Chief Executive Officer |
Mar 04 '26 |
Option Exercise |
0.00 |
788 |
0 |
21,567 |
| Pauling David | Chief Admin. Ofcr. & GC |
Mar 02 '26 |
Option Exercise |
0.00 |
2,356 |
0 |
10,320 |
| Pauling David | Chief Admin. Ofcr. & GC |
Mar 01 '26 |
Option Exercise |
0.00 |
1,342 |
0 |
8,515 |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER |
Mar 02 '26 |
Option Exercise |
0.00 |
2,843 |
0 |
10,688 |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER |
Mar 01 '26 |
Option Exercise |
0.00 |
1,125 |
0 |
8,308 |
| Chung Jane | Chief Executive Officer |
Mar 02 '26 |
Option Exercise |
0.00 |
7,750 |
0 |
23,558 |
| Chung Jane | Chief Executive Officer |
Mar 01 '26 |
Option Exercise |
0.00 |
3,188 |
0 |
17,079 |
0.14%
0.48%
자본화:
|
볼륨(24시간):